Cargando…

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8(+) cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakova, Jana, Truxova, Iva, Holicek, Peter, Salek, Cyril, Hensler, Michal, Kasikova, Lenka, Pasulka, Josef, Holubova, Monika, Kovar, Marek, Lysak, Daniel, Kline, Justin P., Racil, Zdenek, Galluzzi, Lorenzo, Spisek, Radek, Fucikova, Jitka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946028/ https://www.ncbi.nlm.nih.gov/pubmed/33758676 http://dx.doi.org/10.1080/2162402X.2021.1889822

Ejemplares similares

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
por: Holicek, Peter, et al.
Publicado: (2023)

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
por: Truxova, Iva, et al.
Publicado: (2020)

Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
por: Truxova, Iva, et al.
Publicado: (2023)

Calreticulin arms NK cells against leukemia
por: Fucikova, Jitka, et al.
Publicado: (2019)

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients
por: Kasikova, Lenka, et al.
Publicado: (2019)

Detection of immunogenic cell death and its relevance for cancer therapy
por: Fucikova, Jitka, et al.
Publicado: (2020)

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients
por: Truxova, Iva, et al.
Publicado: (2018)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines
por: Hensler, Michal, et al.
Publicado: (2022)

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
por: Fucikova, Jitka, et al.
Publicado: (2019)

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy
por: MIKYŠKOVÁ, ROMANA, et al.
Publicado: (2015)

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
por: Partlová, Simona, et al.
Publicado: (2015)

Immunological configuration of ovarian carcinoma: features and impact on disease outcome
por: Fucikova, Jitka, et al.
Publicado: (2021)

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
por: Fucikova, Jitka, et al.
Publicado: (2015)

Trial watch: Peptide-based vaccines in anticancer therapy
por: Bezu, Lucillia, et al.
Publicado: (2018)

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
por: Adkins, Irena, et al.
Publicado: (2015)

Corrigendum: “Combinatorial Strategies for the Induction of Immunogenic Cell Death”
por: Bezu, Lucillia, et al.
Publicado: (2015)

Combinatorial Strategies for the Induction of Immunogenic Cell Death
por: Bezu, Lucillia, et al.
Publicado: (2015)

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
por: Yamazaki, Takahiro, et al.
Publicado: (2021)

RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment
por: Čermák, Vladimír, et al.
Publicado: (2018)

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
por: Vanmeerbeek, Isaure, et al.
Publicado: (2020)

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
por: Dama, Paola, et al.
Publicado: (2019)

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
por: Pilones, Karsten A., et al.
Publicado: (2020)

Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
por: Fučíková, Jitka, et al.
Publicado: (2011)

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
por: Xu, Liangjing, et al.
Publicado: (2017)

Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms
por: Grohová, Anna, et al.
Publicado: (2020)

Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?
por: Grohová, Anna, et al.
Publicado: (2019)

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022)

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines
por: Kloudová, Kamila, et al.
Publicado: (2016)

TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes
por: Hong, Jian, et al.
Publicado: (2022)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity
por: Antosova, Zuzana, et al.
Publicado: (2022)

NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment
por: Dáňová, Klára, et al.
Publicado: (2015)

PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
por: Kong, Y, et al.
Publicado: (2015)

Tim Burton /
por: Marcos Arza, Marcos
Publicado: (2007)

Tim Lou
por: Lou, Hou Keong
Publicado: (2009)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ano3chhttuptn0jv2o3aps1kma